regulatory considerations in demonstrating complex api sameness
Published 3 years ago • 1.5K plays • Length 24:21Download video MP4
Download video MP3
Similar videos
-
16:13
considerations in demonstrating complex api sameness (7of39) complex generics 2018
-
19:36
strategies to demonstrate complex api sameness (10of35) complex generics – sep. 25-26, 2019
-
22:09
regulatory considerations for synthetic and semi-synthetic oligosaccharide complex apis in generics
-
22:14
synthetic therapeutic peptide apis: documentation for api sameness & related impurities
-
13:21
synthetic therapeutic polymers: documentation for api sameness
-
16:15
formulation assessments: general q1/q2 inquiries to supporting complex excipient sameness
-
20:51
strategies to demonstrate complex excipient sameness (15of35) complex generics – sep. 25-26, 2019
-
20:20
quality considerations for continuous manufacturing of apis
-
19:07
be approaches for long acting drug products (14of35) complex generics – sep. 25-26, 2019
-
12:52
cocrystal apis: documentation
-
16:19
referencing approved drug products in anda submissions (9of28) generic drugs forum – apr. 3-4, 2019
-
24:34
dose-scale analysis in pharmacodynamic equivalence (31of35) complex generics – sep. 25-26, 2019
-
19:24
anda policy and regulatory considerations prior to filing (12/28) generic drugs forum 2017
-
20:18
related impurities assessment considerations for apis in the generic complex peptide products
-
19:32
assessment of complex drug product – physicochemical characteristics to support in vitro be studies
-
31:18
pre-anda logistics and best practices (27of39) complex generics 2018
-
17:27
pre-anda review: office of pharmaceutical quality (opq) (4of39) complex generics 2018
-
25:59
fda’s inactive ingredient database (iid) (3of35) complex generics – sep. 25-26, 2019
-
16:56
global generic drug landscape